The American Journal of Gastroenterology · 2001 · 50 citations · 7 references
MedicinePathologyHepatic PharmacotherapyHepatologyHepatotoxicologyBiliary Tract DiseaseBiliary Tract DisordersHepatic PathologyHepatobiliary DiseaseLiver DiseaseMetabolic Liver DiseaseBiliary AnatomyCholestasis PathophysiologyCholestasis ResolutionCholestatic JaundiceExtrahepatic CholestasisJaundice PathogenesisPercutaneous Liver Biopsy
We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride. Ultrasound of the liver and abdominal CT were normal. An ERCP showed normal biliary anatomy. A percutaneous liver biopsy was obtained showing marked cholestasis, with portal edema, ductular proliferation, and acute inflammation. Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months. Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.
7
Metabolic Effects of Metformin in Non-Insulin-Dependent Diabetes Mellitus
Michael Stümvoll, N. Nurjhan, G. Perriello et al. · New England Journal of Medicine · 1995 · 1.1K citations · Full text
Disposition of metformin (N,N‐dimethylbiguanide) in man
Cesare R. Sirtori, Guido Franceschini, M. Galli-Kienle et al. · Clinical Pharmacology & Therapeutics · 1978 · 220 citations
Clinical relevance of biocompatibility.
Koch Km · PubMed · 1994 · 26 citations
Medicine, Biochemistry, Diabetology +13
Cholestatic jaundice associated with lovastatin (Mevacor) therapy.
Matthew McQueen · PubMed · 1990 · 21 citations